Home→Courses→Advanced Inhalation Product Testing and Quality Training Course
Biotechnology and Pharmaceutical Development
Advanced Inhalation Product Testing and Quality Training Course
Introduction
The successful development and quality control of Orally Inhaled and Nasal Drug Products (OINDPs) is a highly specialized and rapidly evolving field critical for treating respiratory diseases like asthma and COPD. This advanced training program is engineered to address the growing global demand for expertise in In Vitro Bioequivalence (IVBE), Analytical Method Validation, and regulatory compliance. Advanced Inhalation Product Testing and Quality Training Course provides a deep dive into the Critical Quality Attributes (CQAs) of inhalation products, focusing on the sophisticated analytical methodologies required to ensure patient safety and therapeutic efficacy. Participants will master the intricacies of performance testing, including Aerodynamic Particle Size Distribution (APSD) and Delivered Dose Uniformity (DDU), which are foundational to demonstrating product quality and interchangeability across different markets.
The curriculum places a strong emphasis on practical application and compliance with major global pharmacopeial standards and regulatory guidance. Through a blend of theoretical knowledge, hands-on lab techniques, and real-world Case Studies, attendees will learn to navigate the complex Regulatory Landscape for generic and novel inhaled products. We explore advanced topics such as Extractables and Leachables (E&L), Quality by Design (QbD) principles in product development, and the implementation of Data Integrity protocols. By equipping professionals with Advanced Analytical Techniques and a comprehensive understanding of Product Lifecycle Management, this course is the essential next step for individuals looking to become leaders in the Respiratory Drug Delivery and Pharmaceutical Quality sectors.
Programme Curriculum
Advanced Inhalation Product Testing and Quality Training Course
Introduction
The successful development and quality control of Orally Inhaled and Nasal Drug Products (OINDPs) is a highly specialized and rapidly evolving field critical for treating respiratory diseases like asthma and COPD. This advanced training program is engineered to address the growing global demand for expertise in In Vitro Bioequivalence (IVBE), Analytical Method Validation, and regulatory compliance. Advanced Inhalation Product Testing and Quality Training Course provides a deep dive into the Critical Quality Attributes (CQAs) of inhalation products, focusing on the sophisticated analytical methodologies required to ensure patient safety and therapeutic efficacy. Participants will master the intricacies of performance testing, including Aerodynamic Particle Size Distribution (APSD) and Delivered Dose Uniformity (DDU), which are foundational to demonstrating product quality and interchangeability across different markets.
The curriculum places a strong emphasis on practical application and compliance with major global pharmacopeial standards and regulatory guidance. Through a blend of theoretical knowledge, hands-on lab techniques, and real-world Case Studies, attendees will learn to navigate the complex Regulatory Landscape for generic and novel inhaled products. We explore advanced topics such as Extractables and Leachables (E&L), Quality by Design (QbD) principles in product development, and the implementation of Data Integrity protocols. By equipping professionals with Advanced Analytical Techniques and a comprehensive understanding of Product Lifecycle Management, this course is the essential next step for individuals looking to become leaders in the Respiratory Drug Delivery and Pharmaceutical Quality sectors.
Course Duration
10 days
Course Objectives
Master the principles and execution of Delivered Dose Uniformity (DDU) testing for all OINDP types per current pharmacopeia guidelines.
Perform and interpret Aerodynamic Particle Size Distribution (APSD) analysis using the Next Generation Impactor (NGI) and other advanced tools.
Develop and validate Advanced Analytical Methods for inhalation products, ensuring ICH Q2(R1) compliance and robustness.
Apply Quality by Design principles to optimize formulation and manufacturing processes for reproducible product performance.
Design and execute comprehensive Extractable and Leachable (E&L) studies for container closure and device components.
Formulate a robust Regulatory Strategy for global submissions focusing on In Vitro Bioequivalence (IVBE).
Troubleshoot common analytical and performance testing failures specific to respiratory drug products.
Understand the quality and testing challenges associated with emerging fields like Inhaled Biologics and gene therapy.
Implement Data Integrity and GMP compliance standards throughout the inhalation testing laboratory.
Interpret and apply complex Pharmacopeia Requirements from USP ⟨601⟩, Ph. Eur. 2.9.18, and relevant FDA/EMA guidance documents.
Characterize and control the Critical Quality Attributes (CQAs) of drug substance and excipients
Evaluate and verify the performance of different Inhaler Device Types
Lead Product Lifecycle Management activities, including post-approval changes and stability protocol management.
Target Audience
Analytical Scientists and Chemists in Quality Control (QC) or R&D.
Quality Assurance (QA) and Compliance Managers.
Regulatory Affairs Professionals specializing in CMC for respiratory products.
Formulation Scientists and Product Development Engineers.
Technical Directors and Lab Supervisors overseeing OINDP testing.
Professionals from Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs).
Pharmaceutical Engineers involved in device design and process validation.
Auditors and Inspectors from Regulatory Bodies.
Course Outline
Module 1: Foundational Principles of Respiratory Drug Delivery
OINDPs Classification.
Anatomy and physiology of the lung as a drug target.
DDU, APSD, Fine Particle Fraction (FPF).
Introduction to Pharmacopeia Requirements and global standards.
Case Study: Correlating CQA failure with potential patient health risk.
Upon successful completion of this training, participants will be issued with a globally- recognized certificate.
Tailor-Made Course
We also offer tailor-made courses based on your needs.
Key Notes
a. The participant must be conversant with English.
b. Upon completion of training the participant will be issued with an Authorized Training Certificate
c. Course duration is flexible and the contents can be modified to fit any number of days.
d. The course fee includes facilitation training materials, 2 coffee breaks, buffet lunch and A Certificate upon successful completion of Training.
e. One-year post-training support Consultation and Coaching provided after the course.
f. Payment should be done at least a week before commence of the training, to FINESKILL TRAINING CENTER account, as indicated in the invoice so as to enable us prepare better for you.